Four Breast Cancer/Environment Research Centers Created

Publication
Article
OncologyONCOLOGY Vol 18 No 1
Volume 18
Issue 1

Four newly created Breast Cancer and the Environment ResearchCenters will work together in a $35 million effort to investigatethe prenatal to adult environmental factors that may predisposewoman to developing breast cancer. The centers, jointly financed bythe National Cancer Institute and the National Institute of EnvironmentalHealth Sciences, will receive $5 million annually for 7 years.

Four newly created Breast Cancer and the Environment Research Centers will work together in a $35 million effort to investigate the prenatal to adult environmental factors that may predispose woman to developing breast cancer. The centers, jointly financed by the National Cancer Institute and the National Institute of Environmental Health Sciences, will receive $5 million annually for 7 years. The new research centers will be located at the University of Cincinnati, Fox Chase Cancer Center, University of California, San Francisco, and Michigan State University, East Lansing. The quartet will act as a single program, although with some specialization at each center, and will collaborate on several research fronts.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.